Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity

Abstract

Clearance of bevacizumab from the bloodstream in premature infants takes at least 2 months. Although serum free VEGF levels decreased following either laser or bevacizumab treatment, the reductions were more significant in the IVB-treated groups. Potential long-term effects of systemic exposure to bevacizumab in infants need to be studied further.